Valuation Charles River Laboratories International, Inc. Berne S.E.
Stocks
RV6
US1598641074
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 186.14 CHF | +0.96% |
|
+2.54% | - |
| 07-20 | Analyst recommendations: Global Payments, Charles Schwab, US Bancorp, Datadog, Netflix… |  |
| 07-13 | BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220 | MT |
Company Valuation: Charles River Laboratories International, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 18,941 | 11,138 | 12,252 | 9,520 | 10,023 | 10,914 | - | - |
| Change | - | -41.2% | 10% | -22.3% | 5.29% | 8.89% | - | - |
| Enterprise Value (EV) 1 | 21,366 | 13,616 | 14,622 | 11,565 | 11,946 | 12,727 | 12,299 | 11,918 |
| Change | - | -36.28% | 7.39% | -20.91% | 3.29% | 6.54% | -3.37% | -3.1% |
| P/E | 49.4x | 23.1x | 25.9x | 931x | -70x | 37x | 24.8x | 22.8x |
| PBR | 7.45x | 3.75x | 3.41x | 2.75x | 3.17x | 3.31x | 2.96x | 2.68x |
| PEG | - | 0.9x | -9.44x | -9.5x | 0x | -0x | 0.5x | 2.62x |
| Capitalization / Revenue | 5.35x | 2.8x | 2.97x | 2.35x | 2.5x | 2.84x | 2.78x | 2.66x |
| EV / Revenue | 6.04x | 3.42x | 3.54x | 2.86x | 2.98x | 3.31x | 3.14x | 2.91x |
| EV / EBITDA | 24.3x | 13.7x | 14.4x | 11.6x | 12.3x | 12.9x | 11.7x | 10.6x |
| EV / EBIT | 28.8x | 16.3x | 17.4x | 14.3x | 15x | 15.7x | 13.9x | 12.5x |
| EV / FCF | 40.2x | 46.2x | 40x | 23.1x | 23x | 24.7x | 19.8x | 37.9x |
| FCF Yield | 2.49% | 2.17% | 2.5% | 4.34% | 4.34% | 4.05% | 5.05% | 2.64% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 7.6 | 9.48 | 9.22 | 0.2 | -2.91 | 6.131 | 9.153 | 9.949 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 3,540 | 3,976 | 4,129 | 4,050 | 4,015 | 3,848 | 3,923 | 4,099 |
| EBITDA 1 | 879.5 | 990.9 | 1,013 | 996.1 | 971.5 | 990.4 | 1,053 | 1,120 |
| EBIT 1 | 742.1 | 834 | 838.8 | 805.9 | 793.9 | 811.4 | 883.7 | 949.7 |
| Net income 1 | 391 | 486.2 | 474.6 | 10.3 | -144.3 | 285.1 | 417.3 | 447 |
| Net Debt 1 | 2,425 | 2,477 | 2,370 | 2,046 | 1,923 | 1,814 | 1,385 | 1,004 |
| Reference price 2 | 375.34 | 218.92 | 238.84 | 186.16 | 203.66 | 226.58 | 226.58 | 226.58 |
| Nbr of stocks (in thousands) | 50,464 | 50,879 | 51,297 | 51,136 | 49,215 | 48,168 | - | - |
| Announcement Date | 2/16/22 | 2/22/23 | 2/14/24 | 2/19/25 | 2/18/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.24x | 5.76x | 17.3x | 1.02% | 46.86B | |
| -23.62x | 354.58x | -21.66x | -.--% | 40.23B | |
| 48.91x | 4.94x | 31.87x | -.--% | 36.23B | |
| 25.32x | 2.8x | 12.1x | -.--% | 34.72B | |
| 27.42x | 8.04x | 20.17x | 0.41% | 27.89B | |
| 34.31x | 5.61x | 25.58x | -.--% | 16.79B | |
| 22.5x | 1.95x | 8.49x | 1.18% | 13.12B | |
| 23.43x | 1.87x | 11.34x | -.--% | 12.7B | |
| Average | 23.81x | 48.19x | 13.15x | 0.33% | 28.57B | |
| Weighted average by Cap. | 22.51x | 66.41x | 12.08x | 0.33% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CRL Stock
- RV6 Stock
- Valuation Charles River Laboratories International, Inc.
Select your edition
All financial news and data tailored to specific country editions
